Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
接受 CD3xCD123 双特异性抗体 APVO436 治疗的复发/难治性 AML 或 MDS 患者的细胞因子释放综合征风险、特征和生物标志物
期刊:Cancers
影响因子:
doi:10.3390/cancers13215287
Fatih M Uckun, Justin Watts, Alice S Mims, Prapti Patel, Eunice Wang, Paul J Shami, Elizabeth Cull, Cynthia Lee, Christopher R Cogle, Tara L Lin
